Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance

Journal of Addiction Medicine

Volumn 8, Issue 4, 2014, Pages 249-257

  Zeremski, Marija ^a   Dimova, Rositsa B ^a,b   Zavala, Roberto ^a,c   Kritz, Steven ^c   Lin, Melissa ^c   Smith, Bryce D ^d   Zibbell, Jon E ^d   Talal, Andrew H ^a,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Addiction Research and Treatment Corporation   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

Drug treatment; HCV education; Knowledge; Models of care for hepatitis C; Persons who inject drugs

Indexed keywords

METHADONE;

ATTITUDE TO HEALTH; COMPLICATION; FEMALE; HEALTH EDUCATION; HEALTH SURVEY; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PSYCHOLOGY; SUBSTANCE ABUSE;

FEMALE; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HEPATITIS C; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84905853237     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000041     Document Type: Article

References (36)

1. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis 2008;46(12):1852-1858.
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705-714.
3. Balfour L, Kowal J, Corace KM, et al. Increasing public awareness about hepatitis C: development and validation of the brief hepatitis C knowledge scale. Scand J Caring Sci 2009;23(4):801-808.
4. Bini EJ, Kritz S, Brown LS Jr, et al. Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis 2011;30(2):98-109.
5. Bini EJ, Kritz S, Brown LS Jr, et al. Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States. J Subst Abuse Treat 2012;42(4):438-445.
6. Carey J, Perlman DC, Friedmann P, et al. Knowledge of hepatitis among active drug injectors at a syringe exchange program. J Subst Abuse Treat 2005;29(1):47-53.
7. Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31(8):1090-1101.
8. Chen EY, North CS, Fatunde O, et al. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults. J Viral Hepat 2013;20(10): 708-714.
9. Cohen-Moreno R, Schiff M, Levitt S, et al. Knowledge about hepatitis-C among methadone maintenance treatment patients in Israel. Subst Use Misuse 2010;45(1/2):58-76.
10. Denniston MM, Klevens RM, Mcquillan GM, et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 2012;55(6):1652-1661.
11. Dimova RB, Zeremski M, Jacobson IM, et al. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013;56(6):806-816.
12. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005;40(suppl 5):S313-S320.
13. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006;42(5):673-676.
14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-982.
15. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitisCvirusinfection among illicit drugusers.Drug Alcohol Depend 2008;93(1/2):141-147.
16. Jacobson IM, Mchutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-2416.
17. Krauskopf K, McGinn TG, Federman AD, et al. HIV and HCV health beliefs in an inner-city community. J Viral Hepat 2011;18(11):785-791.
18. Kwo PY, Lawitz EJ, Mccone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and rib-avirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376(9742):705- 716.
19. Manns MP, Mchutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus rib-avirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-965.
20. Martinez AD, Dimova R, Marks KM, et al. Integrated internist-addiction medicine-hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2012;19(1):47-54.
21. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008;33(3): 126-133.
22. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005;20(8):754-758.
23. Myles A, Mugford GJ, Zhao J, et al. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol 2011;25(3):135-139.
24. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378(9791):571-583.
25. Park JN, White B, Bates A, et al. Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs. Drug Alcohol Depend 2012;123(1-3):35-40.
26. Perlman DC, Friedmann P, Horn L, et al. Impact of monetary incentives on adherence to referral for screening chest x-rays after syringe exchange-based tuberculin skin testing. J Urban Health 2003;80(3):428-437.
27. Schackman BR, Teixeira PA, Beeder AB. Offers of hepatitis C care do not lead to treatment. J Urban Health 2007;84(3):455-458.
28. Shah HA, Abu-Amara M. Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. Clin Gastroenterol Hepatol 2013;11(8):922-933.
29. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001;61(3):211-215.
30. Strathdee SA, Latka M, Campbell J, et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005;40(suppl 5):S304-S312.
31. Strauss SM, Astone-Twerell J, Munoz-Plaza CE, et al. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res 2007;7:39.
32. Treloar C, Hull P, Dore GJ, et al. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev 2012;31(7):918-924.
33. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012;26(4):487-503.
34. Walley AY, White MC, Kushel MB, et al. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005;28(2):181-187.
35. World Health Organization. Hepatitis C. Fact sheet no. 164. Available at http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed August 21, 2013.
36. Zeremski M, Zibbell JE, Martinez AD, et al. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. Wo r l d J Gastroenterol 2013;19(44):7846-7851.